Destiny Pharma plc (AIM: DEST), a clinical stage innovative biotechnology company focused on the development of novel medicines that can prevent life-threatening infections, today announces very encouraging results from its collaboration with SporeGen Limited ("SporeGen"), a UK biotechnology company working .
Research Analysts’ updated eps estimates for Thursday, April 13th: Anglo American (LON:AAL) had its top pick rating reaffirmed by analysts at Citigroup Inc.. Clarkson (LON:CKN) had its neutral rating reiterated by analysts at JPMorgan Chase & Co.. The firm currently has a GBX 3,740 ($46.32) target price on the stock. Destiny Pharma (LON:DEST) had its […]